-
Hasten Biopharmaceutical Expands into Pan-Asia Regions with Celltrion Asset Acquisition
•
Hasten Biopharmaceutical Co., Ltd, a China-based pharmaceutical company backed by CBC Group, has announced an asset acquisition agreement with South Korean biopharmaceutical company Celltrion (KRX: 068270). The deal focuses on 14 branded products across various pan-Asia countries and regions, as well as the Marketing Authorization Holder (MAH) rights for these…
-
Dr. Reddy’s Launches Biosimilar Versavo in UK to Challenge Roche’s Cancer Therapy Avastin
•
Dr. Reddy’s Laboratories (NYSE: RDY), a prominent Indian pharmaceutical company, has launched its biosimilar Versavo (bevacizumab) in the UK market, presenting a challenge to Roche’s established cancer therapy Avastin. Versavo, a biosimilar to Avastin, has been approved for the treatment of various metastatic cancers, including colorectal cancer, non-squamous non-small cell…
-
Celltrion’s Infliximab Biosimilar Shows Promising Long-Term Efficacy and Safety in CD and UC
•
South Korean biopharmaceutical company Celltrion (KRX: 068270) has presented positive long-term efficacy and safety data for its infliximab biosimilar in the treatment of Crohn’s disease (CD) and ulcerative colitis (UC). The biosimilar offers the advantage of subcutaneous administration, providing a more convenient alternative to Johnson & Johnson’s (J&J; NYSE: JNJ)…
-
WuXi XDC Partners with Celltrion to Support Global Development and Manufacturing of Bioconjugated Drugs
•
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA, a subsidiary of WuXi AppTec Co., Ltd (SHA: 603259), has announced a cooperation memorandum of understanding (MOU) with South Korean firm Celltrion Inc. (KRX: 068270) to provide comprehensive services for the development and manufacturing of…
